Tamsulosin and cataract surgery complications

Article

According to a report in the Journal of the American Medical Association patients taking tamsulosin for benign prostrate enlargement within 14 days of cataract surgery may have an increased risk of complications.

According to a report in the Journal of the American Medical Association patients taking tamsulosin for benign prostrate enlargement within 14 days of cataract surgery may have an increased risk of complications.

Other similar medications do not increase the risk of these complications — which include lens loss, retinal detachment, and inflammation — according to Dr Chaim M. Bell, from St. Michael's Hospital, Toronto, and colleagues.

The findings hail from a study of 96,128 men, 66 years or older, who underwent cataract surgery in Ontario, Canada from 2002 to 2007. Of these patients, 3550 had taken tamsulosin within 14 days of surgery and 7426 had recent taken other so-called alpha-blocking agents.

Overall, 284 patients experienced an adverse event related to cataract surgery, and 280 of them were matched by age, surgeon, and year of surgery to 1102 patients who did not experience complications.

The report shows that the patients with complications were 2.3 times more likely to have recently taken tamsulosin than the comparison group. By contrast, no significant differences were noted in recent or prior exposure to other alpha-blockers.

The researchers calculate that for every 255 cataract surgery patients who have recently taken tamsulosin, one will develop a serious postop complication.

"Because the combination of cataract surgery and tamsulosin exposure is relatively common, patients should be properly appraised of the risks of drug therapy, and preoperative systems should focus on the identification of tamsulosin use by patients," the authors concluded.

SOURCE: Journal of the American Medical Association.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.